Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[New pharmacological approaches: rhDNase]

G Tournier1, A Sardet, C Grosskopf

  • 1Service de Pédiatrie et de Pneumologie de l'Enfant, Hôpital d'Enfants Armand Trousseau, Paris.

Revue De Pneumologie Clinique
|January 1, 1995
PubMed
Summary

Recombinant human deoxyribonuclease (rhDNase) is a novel cystic fibrosis treatment targeting respiratory tract infections. This therapy reduces infections and enhances lung function in eligible patients, improving their quality of life.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vaccine coverage in CF children: A French multicenter study.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2015
Same author

[Inhaled treatments in cystic fibrosis: what's new in 2013?].

Revue des maladies respiratoires·2014
Same author

[News in cystic fibrosis].

Revue de pneumologie clinique·2013
Same author

[Intricated asthma tracheomalacia: diagnosis and therapeutic aspects].

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2009
Same author

Lung disease in ataxia-telangiectasia.

Acta paediatrica (Oslo, Norway : 1992)·2007
Same author

[Fatal evolution of a dilated cardiomyopathy during a primary Epstein-Barr virus infection].

Annales de biologie clinique·2006

Area of Science:

  • Pulmonary Medicine
  • Biochemistry

Context:

  • Cystic fibrosis (CF) is a genetic disorder characterized by thick, sticky mucus in the lungs.
  • Extracellular DNA (eDNA) is a major component of CF sputum, contributing to its viscosity and inflammatory properties.

Purpose:

  • To evaluate the efficacy of recombinant human deoxyribonuclease (rhDNase) in managing cystic fibrosis.
  • To assess the impact of rhDNase on respiratory infections and lung function in CF patients.

Summary:

  • rhDNase targets and degrades extracellular DNA in bronchial secretions, reducing mucus viscosity.
  • Clinical studies show rhDNase significantly decreases respiratory infection rates and improves pulmonary function in CF patients over 5 years old.
  • Optimal use involves combination therapy with existing treatments and synchronized respiratory exercises.

Related Experiment Videos

Impact:

  • rhDNase represents a targeted therapy for cystic fibrosis, addressing a key pathological feature.
  • This treatment offers a significant improvement in respiratory health and potentially reduces hospitalizations for CF patients.
  • Further research is needed to fully ascertain the long-term therapeutic benefits of rhDNase.